October 26, 2022Open Access

Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations

Key Points

Key points are not available for this paper at this time.

Abstract

GSK2256098 was well tolerated and resulted in an improved PFS6 rate in patients with recurrent or progressive NF2-mutated meningiomas, compared with historical controls. The criteria for promising activity were met, and FAK inhibition warrants further evaluation for this patient population.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Priscilla K. Brastianos

Erin Twohy

Elizabeth R. Gerstner

Journals

Journal of Clinical Oncology

Actions

Institutions

Harvard University

Johns Hopkins University

University of California, San Francisco

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study